Refine
Has Fulltext
- yes (4)
Is part of the Bibliography
- yes (4)
Document Type
- Journal article (3)
- Doctoral Thesis (1)
Keywords
- Bacteria (1)
- Bone-marrow-transplantation (1)
- Candida albicans (1)
- Fungal (1)
- Hepatitis B virus (1)
- Herpes simplex virus (1)
- Human immunodefiency virus (1)
- Infections (1)
- Influenzae type B (1)
- Low-dose acyclovir (1)
Objectives
Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs). Study aim was to analyze treatment strategies and clinical effectiveness.
Methods
We set up a web-based registry on
www.ClinicalSurveys.net
for documentation of comprehensive data of patients who received novel POS formulations. Data analysis was split into two groups of patients who received novel POS formulations for antifungal prophylaxis (posaconazole prophylaxis group) and antifungal therapy (posaconazole therapy group), respectively.
Results
Overall, 180 patients (151 in the posaconazole prophylaxis group and 29 in the posaconazole therapy group) from six German tertiary care centers and hospitalized between 05/2014 – 03/2016 were observed. Median age was 58 years (range: 19 – 77 years) and the most common risk factor for IFD was chemotherapy (n = 136; 76%). In the posaconazole prophylaxis group and posaconazole therapy group, median POS serum levels at steady-state were 1,068 μg/L (IQR 573–1,498 μg/L) and 904 μg/L (IQR 728–1,550 μg/L), respectively (P = 0.776). During antifungal prophylaxis with POS, nine (6%) probable/proven fungal breakthroughs were reported and overall survival rate of hospitalization was 86%. The median overall duration of POS therapy was 18 days (IQR: 7 – 23 days). Fourteen patients (48%) had progressive IFD under POS therapy, of these five patients (36%) died related to or likely related to IFD.
Conclusions
Our study demonstrates clinical effectiveness of antifungal prophylaxis with novel POS formulations. In patients treated for possible/probable/proven IFD, we observed considerable mortality in patients receiving salvage treatment and with infections due to rare fungal species.
Background
Patients with acute leukaemia have a high incidence of fungal infections. This has primarily been shown in acute myeloid leukaemia and is different for acute lymphoblastic leukaemia. Until now no benefit of mould active prophylaxis has been demonstrated in the latter population.
Methods
In this retrospective single‐centre study, we analysed the incidence, clinical relevance, and outcome of invasive fungal diseases (IFD) as well as the impact of antifungal prophylaxis for the first 100 days following the primary diagnosis of acute lymphoblastic leukaemia.
Results
In 58 patients a high rate of proven, probable, and possible fungal infections could be demonstrated with a 3.4%, 8.6%, and 17.2% likelihood, respectively. The incidence might be even higher, as nearly 40% of all patients had no prolonged neutropenia for more than 10 days, excluding those from the European Organization of Research and Treatment of cancer and the Mycoses Study Group criteria for probable invasive fungal disease. The diagnosed fungal diseases had an impact on the duration of hospitalisation, which was 13 days longer for patients with proven/probable IFD compared to patients with no signs of fungal infection. Use of antifungal prophylaxis did not significantly affect the risk of fungal infection.
Conclusion
Patients with acute lymphoblastic leukaemia are at high risk of acquiring an invasive fungal disease. Appropriate criteria to define fungal infections, especially in this population, and strategies to reduce the risk of infection, including antifungal prophylaxis, need to be further evaluated.
Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.
Es konnte mit PHR3 bei Candida albicans ein drittes GAS-homologes Gen nachgewiesen werden. Dieses weist überzeugende Übereinstimmungen der Nuklein- und Aminosäurensequenz und mit der fehlenden GPI-Verankerungsstelle und der pH-konstitutiven Expression auch interessante Unterschiede zu den bisher bekannten Genen der PHR-Familie auf. Eine funktionelle Homologie zu den weiteren PHR-Genen bei Candida albicans konnte nicht belegt werden. Es sind bisher in verschiedenen Spezies mehrere homologe Gene dieser Familie nachgewiesen worden. So sind auch bei Candida albicans weitere möglich und die endgültige Zahl der PHR-Gene wird erst nach Abschluß des Candida albicans-Genomprojektes bestimmt werden können. Der Zweck mehrerer homologer Gene ist insbesondere für die bei unterschiedlichen pH-Werten vorliegenden Proteine Phr1p und Phr2p noch nicht bekannt. Eine mögliche Erklärung ist, dass ihre Translation auf unterschiedliche Weise die Expression anderer Gene oder die Prozessierung und Funktion von Proteinen beeinflusst. Eine solche feine Regulation von Wachstums- und Virulenzfaktoren und somit eine Anpassung an Umweltbedingungen und Infektionswege ist für die Pathogenität von Candida albicans von Bedeutung. Die spezifischen Faktoren für die Induktion von PHR3 sind, sollte eine differenzierte Regulation vorliegen, dagegen ebenso wenig wie für GAS4, als nähestes verwandtes Gen, und für die weiteren GAS-Gene bekannt. Zum Nachweis einer solchen signalspezifischen Transkription sind Experimente mit anderen Versuchsanordnungen, mit welchen sich komplexere Milieus und Infektionswege untersuchen lassen, wie DNA-Chips oder induktionsabhängige Signalkassetten (Morschhäuser et al., 1999; Staib et al., 1999) hilfreich. Da eine fehlende C-terminale Region bei GAS1 zur Sekretion eines vergrößerten Proteins mit Hypermannosylierung der serinreichen Region führt (Popolo et Vai, 1998), erscheint auch eine extrazelluläre Funktion von Phr3p, welches dieses hydrophobe 3’ Ende nativ nicht besitzt, möglich. Dabei ist eine zu Phr1p und Phr2p ähnliche oder gleiche enzymatische Funktion, welche in Diskussion 112 unterschiedlichen Kompartimenten oder von unterschiedlicher Lokalisation aus den Aufbau der Zellwand beeinflusst, denkbar.